MHRA drug safety update: zoledronic acid

8th July 2010

The April issue of the MHRA drug safety update reminds health professionals about the use of intravenous zoledronic acid and adverse effects on renal function. Zoledronic acid is associated with reports of renal impairment and renal failure, especially in patients with pre-existing renal dysfunction or other risk factors. Renal function should be measured before each dose, and patients should be adequately hydrated before treatment. Renal function monitoring is recommended after use of zoledronic acid in at-risk patients and those with pre-existing renal impairment. Use in patients with severe renal impairment is generally not recommended, but may be considered for tumour-induced hypercalcaemia, if the benefits outweigh the risks.
For further information see the original article and the PCF monograph for zoledronic acid.

MHRA drug safety update April
PCF zoledronic acid monograph